: Alzheimer's disease (AD), a central cause of dementia, is characterized by the accumulation of amyloid β- peptide (Aβ) peptides in the brain. P-glycoprotein (P-gp), a highly expressed protein in the BBB, plays a fundamental role in transporting Aβ from the brain to the blood and protecting the blood-brain barrier (BBB). The dysfunction or decreased abundance of this transporting protein is associated with the accumulation of Aβ, leading to dementia and cognitive deficits. In this review article, we consolidate the existing literature on the impact of P-gp in the pathophysiology and therapy of AD. Current evidence claims that p-gp is involved in AD pathology and that enhancing the activity of this transporter may be a promising therapeutic approach to hinder AD progression. There is also a growing interest in P-gp as a potential therapeutic target for AD. Hence, ongoing clinical trials and research should investigate P-gp inhibitor efficacy as a therapeutic approach for improving AD drug delivery to the brain and treatment outcomes.

中文翻译：

---

P-糖蛋白在阿尔茨海默病的病理学和治疗中的作用

：阿尔茨海默氏病 (AD) 是痴呆症的主要原因，其特征是淀粉样 β-肽 (Aβ) 肽在大脑中积聚。P-糖蛋白 (P-gp) 是 BBB 中高表达的蛋白质，在将 Aβ 从大脑转运到血液和保护血脑屏障 (BBB) 方面发挥着重要作用。这种转运蛋白的功能障碍或丰度减少与 Aβ 的积累有关，从而导致痴呆和认知缺陷。在这篇综述文章中，我们整合了有关 P-gp 在 AD 病理生理学和治疗中影响的现有文献。目前的证据表明，p-gp 参与 AD 病理学，增强这种转运蛋白的活性可能是阻碍 AD 进展的一种有前途的治疗方法。人们对 P-gp 作为 AD 潜在治疗靶点的兴趣也日益浓厚。因此，正在进行的临床试验和研究应该调查 P-gp 抑制剂作为改善 AD 药物向大脑输送和治疗结果的治疗方法的功效。